AssessmentsAnticoagulants: Direct factor inhibitors
Anticoagulants: Direct factor inhibitors
What is the most common adverse effect of Apixaban and Rivaroxaban (Factor Xa inhibitors)?
Content Reviewers:Yifan Xiao, MD
Anticoagulant medications help to prevent, thrombi, or blood clots from forming.
These medications work by interfering with the normal function of proteins called clotting factors in a chemical process called the coagulation cascade, or secondary hemostasis where hemo refers to blood, and stasis means to halt or stop.
In this video we’re going to focus on direct that work on a single coagulation factor; either thrombin or activated factor X.
Now, before we can discuss how direct inhibitors work, let's take a closer look at the coagulation cascade to see where these medications operate.
The coagulation cascade begins via two pathways --the extrinsic and intrinsic pathways.
The intrinsic pathway starts when circulating factor XII comes into contact with the surface of activated platelets or collagen.
Activated factor XII, then activates factor XI, which activates factor IX which activates factor X.
Factor X starts the common pathway where it activates factor II, or thrombin, which activates factor I that builds the fibrin mesh.
When factor II gets activated it also activates 4 other factors: V, VIII, IX, and XIII.
Factor V gets activated and acts as a cofactor for X, factor VIII acts as a cofactor for factor IX, and factor XIII helps factor I, or fibrin, form crosslinks.
In the extrinsic pathway, exposed tissue factor activates factor VII, which activates factor X and starts the common pathway.
Now, the most important point of clot regulation is when a coagulation factor called thrombin is produced.
Thrombin, or activated factor II, is a very important clotting factor, because it has multiple pro-coagulative functions.
Think of thrombin as the accelerator on a car--the pedal that takes secondary hemostasis from 20 miles per hour to 100 miles per hour!
First, thrombin binds to receptors on platelets causing them to activate.
Second, thrombin activates two cofactors; factor V used in the common pathway, and factor VIII used in the intrinsic pathway.
Third, thrombin proteolytically cleaves fibrinogen or factor I, into fibrin or factor Ia which binds with other fibrin proteins to form a fibrin mesh.
And finally, thrombin proteolytically cleaves stabilizing factor or factor XIII into factor XIIIa.
Factor XIIIa combines with a calcium ion cofactor to form cross links between the fibrin chains, further reinforcing the fibrin mesh.
The direct thrombin inhibitors can bind to thrombin that’s in the circulation and those already attached to a forming clot.
Factor Xa inhibitors have the same function on Xa, however, it has an overall greater effect on anticoagulation since it’s higher up in the coagulation cascade, so each molecule of the medication can prevent multiple thrombins from being activated by a factor Xa.
Now, in terms of laboratory parameters, direct thrombin inhibitors prolong thrombin time, and have less effect on prothrombin time, or PT, which assesses the extrinsic and common coagulation pathways, and partial thromboplastin time, or aPTT, that assesses the intrinsic and common coagulation pathways.
Direct factor Xa inhibitors prolong both PT and aPTT, but have no effect on thrombin time.
However, both classes of direct factor inhibitors do not require routine monitoring.
Now, let's discuss each class of medications in more detail starting with the direct thrombin inhibitors like bivalirudin, lepirudin, and argatroban, which are given intravenously, desirudin, which is given subcutaneously, and dabigatran, which is given peroral.
This class of medications was initially isolated from the saliva of leeches due to its anticoagulant effect.
Although they are not as frequently used as heparin, they can be a 2nd line medication in people with a history of deep vein thrombosis to prevent pulmonary embolism, or atrial fibrillation to prevent strokes.
There is also destruction of platelets by cells of the spleen called macrophages, resulting in a low platelet count.
- "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
- "Rang and Dale's Pharmacology" Elsevier (2019)
- "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
- "Overview of hemostasis" J.C. Aster, H. Bunn (Eds.), Pathophysiology of Blood Disorders, 2e. McGraw-Hill. (2016)
- "Nomograms" D. Nicoll , C. Mark Lu, S.J. McPhee (Eds.), Guide to Diagnostic Tests, 7e. McGraw-Hill (2017)
- "Use of direct oral anticoagulants in daily practice" Am J Blood Res (2018)
- "Manejo de hemorragia asociada a anticoagulantes orales directos: estado actual de las estrategias de reversión" Revista médica de Chile (2019)
- "Anticoagulantes orais diretos para o tratamento da trombose venosa profunda: revisão de revisões sistemáticas" Jornal Vascular Brasileiro (2018)